{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:02:37Z","timestamp":1793116957857,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["BID-PICT-2015-0513"],"award-info":[{"award-number":["BID-PICT-2015-0513"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["BID-PICT-2011-1605"],"award-info":[{"award-number":["BID-PICT-2011-1605"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundacion Felipe Fiorellino"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>ROR2 is a tyrosine-kinase receptor whose expression is dysregulated in many human diseases. In cancer, ROR2 stimulates proliferation, survival, migration, and metastasis, and is associated with more aggressive tumor stages. The purpose of this work is to study the role of ROR2 in the chemoresistance of melanoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Gain- and loss-of-function experiments were used to study the biological function of ROR2 in melanoma. Cell death induced by chemotherapeutic drugs and BH-3 mimetics was evaluated using crystal violet cytotoxicity assays and annexin V\/propidium iodide staining. Western blots were used to evaluate the expression of proteins implicated in cell death. The differences observed between cells with manipulation of ROR2 levels and control cells were evaluated using both Student\u2019s <jats:italic>t<\/jats:italic>-test and ANOVA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We describe that ROR2 contributes to tumor progression by enhancing the resistance of melanoma cells to both chemotherapeutic drugs and BH-3 mimetics. We demonstrate that ROR2 reduced cell death upon treatment with cisplatin, dacarbazine, lomustine, camptothecin, paclitaxel, ABT-737, TW-37, and venetoclax. This effect was mediated by the inhibition of apoptosis. In addition, we investigated the molecular mechanisms implicated in this role of ROR2. We identified the MDM2\/p53 pathway as a novel target of ROR2 since ROR2 positively regulates MDM2 levels, thus leading to p53 downregulation. We also showed that ROR2 also upregulates Mcl-1 and Bcl2-xL while it negatively regulates Bax and Bid expression. The effect of ROR2 on the expression of these proteins is mediated by the hyperactivation of ERK.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results demonstrate that ROR2 contributes to melanoma progression by inhibiting apoptosis and increasing chemoresistance. These results not only position ROR2 as a marker of chemoresistance but also support its use as a novel therapeutic target in cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s11658-022-00327-7","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T11:04:09Z","timestamp":1646737449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation"],"prefix":"10.1186","volume":"27","author":[{"given":"Mar\u00eda Victoria","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gast\u00f3n Alexis","family":"Barbero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"M\u00e1scolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Josefina","family":"Quezada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8669-6931","authenticated-orcid":false,"given":"Pablo","family":"Lopez-Bergami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"issue":"1","key":"327_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA A Cancer J Clin"},{"issue":"5","key":"327_CR2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1755-148X.2010.00745.x","volume":"23","author":"N-Y Yang","year":"2010","unstructured":"Yang N-Y, Lopez-Bergami P, Goydos JS, Yip D, Walker AM, Pasquale EB, et\u00a0al. The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand. Pigment Cell Melanoma Res. 2010;23(5):684\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"327_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1751-1097.2007.00254.x","volume":"84","author":"P Lopez-Bergami","year":"2008","unstructured":"Lopez-Bergami P, Fitchman B, Ronai Z. Understanding signaling cascades in melanoma. Photochem Photobiol. 2008;84(2):289\u2013306.","journal-title":"Photochem Photobiol"},{"issue":"4","key":"327_CR4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.bbamcr.2016.01.025","volume":"1863","author":"J Paluncic","year":"2016","unstructured":"Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, Huang ML-H, et\u00a0al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta Mol Cell Res. 2016;1863(4):770\u201384.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"9","key":"327_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/cells8091060","volume":"8","author":"G Barbero","year":"2019","unstructured":"Barbero G, Castro MV, Villanueva MB, Quezada MJ, Fern\u00e1ndez NB, DeMorrow S, et\u00a0al. An autocrine Wnt5a loop promotes NF-\u03baB pathway activation and cytokine\/chemokine secretion in melanoma. Cells. 2019;8(9):1060.","journal-title":"Cells"},{"issue":"3","key":"327_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10555-020-09878-7","volume":"39","author":"P Lopez-Bergami","year":"2020","unstructured":"Lopez-Bergami P, Barbero G. The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment. Cancer Metastasis Rev. 2020;39(3):933\u201352.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"327_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41419-017-0059-7","volume":"9","author":"G Mattia","year":"2018","unstructured":"Mattia G, Puglisi R, Ascione B, Malorni W, Car\u00e8 A, Matarrese P. Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. Cell Death Dis. 2018;9(2):112.","journal-title":"Cell Death Dis"},{"key":"327_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","volume":"130","author":"S Ugurel","year":"2020","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, et\u00a0al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition\u2014Update 2019. Eur J Cancer. 2020;130:126\u201338.","journal-title":"Eur J Cancer"},{"key":"327_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","volume":"150","author":"Z Debebe","year":"2015","unstructured":"Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharmacol Ther. 2015;150:143\u20138.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"327_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/ijc.27984","volume":"133","author":"CE Ford","year":"2013","unstructured":"Ford CE, Qian Ma SS, Quadir A, Ward RL. The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer. 2013;133(4):779\u201387.","journal-title":"Int J Cancer"},{"key":"327_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103595","volume":"170","author":"MV Castro","year":"2022","unstructured":"Castro MV, Lopez-Bergami P. Cellular and molecular mechanisms implicated in the dual role of ROR2 in cancer. Crit Rev Oncol Hematol. 2022;170:103595.","journal-title":"Crit Rev Oncol Hematol."},{"key":"327_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s11658-016-0003-3","volume":"21","author":"S Arabzadeh","year":"2016","unstructured":"Arabzadeh S, Hossein G, Salehi-Dulabi Z, Zarnani AH. WNT5A-ROR2 is induced by inflammatory mediators and is involved in the migration of human ovarian cancer cell line SKOV-3. Cell Mol Biol Lett. 2016;21:9.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"327_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.gendis.2016.01.002","volume":"3","author":"J Wang","year":"2016","unstructured":"Wang J, Wei Q, Wang X, Tang S, Liu H, Zhang F, et\u00a0al. Transition to resistance: an unexpected role of the EMT in cancer chemoresistance. Genes Dis. 2016;3(1):3\u20136.","journal-title":"Genes Dis"},{"issue":"1","key":"327_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/onc.2009.305","volume":"29","author":"MP O\u2019Connell","year":"2010","unstructured":"O\u2019Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, et\u00a0al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2010;29(1):34\u201344.","journal-title":"Oncogene"},{"issue":"11","key":"327_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cancergen.2012.09.002","volume":"205","author":"S-S Lai","year":"2012","unstructured":"Lai S-S, Xue B, Yang Y, Zhao L, Chu C-S, Hao J-Y, et\u00a0al. Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE. Cancer Genet. 2012;205(11):552\u201362.","journal-title":"Cancer Genet"},{"issue":"1","key":"327_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12929-021-00776-w","volume":"28","author":"MV Castro","year":"2021","unstructured":"Castro MV, Barbero GA, Villanueva MB, Grumolato L, Nsengimana J, Newton-Bishop J, et\u00a0al. ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation. J Biomed Sci. 2021;28(1):76.","journal-title":"J Biomed Sci"},{"key":"327_CR17","doi-asserted-by":"crossref","unstructured":"Castro MV, Barbero G, Villanueva MB, Nsengimana J, Newton-Bishop J, Illescas E, et\u00a0al. ROR2 Promotes EMT and Necrosis by Hyperactivating ERK in Melanoma [Internet]. In Review; 2021. https:\/\/www.researchsquare.com\/article\/rs-1050315\/v1. Accessed 1 Nov 2021.","DOI":"10.21203\/rs.3.rs-1050315\/v1"},{"issue":"1","key":"327_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/cancers13010078","volume":"13","author":"MJ Quezada","year":"2020","unstructured":"Quezada MJ, Picco ME, Villanueva MB, Castro MV, Barbero G, Fern\u00e1ndez NB, et\u00a0al. BCL2L10 is overexpressed in melanoma downstream of STAT3 and promotes cisplatin and ABT-737 resistance. Cancers. 2020;13(1):78.","journal-title":"Cancers"},{"key":"327_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13578-018-0265-8","volume":"9","author":"ME Picco","year":"2019","unstructured":"Picco ME, Castro MV, Quezada MJ, Barbero G, Villanueva MB, Fern\u00e1ndez NB, et\u00a0al. STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1. Cell Biosci. 2019;9:3.","journal-title":"Cell Biosci"},{"issue":"5","key":"327_CR20","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.18632\/oncotarget.13475","volume":"8","author":"K Hientz","year":"2017","unstructured":"Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921\u201346.","journal-title":"Oncotarget"},{"issue":"1","key":"327_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00008390-199802000-00004","volume":"8","author":"G Li","year":"1998","unstructured":"Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res. 1998;8(1):17\u20138.","journal-title":"Melanoma Res"},{"issue":"6","key":"327_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell. 2018;34(6):879\u201391.","journal-title":"Cancer Cell"},{"issue":"7042","key":"327_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et\u00a0al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677\u201381.","journal-title":"Nature"},{"issue":"21","key":"327_CR24","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1021\/jm060460o","volume":"49","author":"G Wang","year":"2006","unstructured":"Wang G, Nikolovska-Coleska Z, Yang C-Y, Wang R, Tang G, Guo J, et\u00a0al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006;49(21):6139\u201342.","journal-title":"J Med Chem"},{"issue":"10","key":"327_CR25","doi-asserted-by":"publisher","first-page":"E2505","DOI":"10.3390\/ijms20102505","volume":"20","author":"IC Salaroglio","year":"2019","unstructured":"Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C. ERK is a pivotal player of chemo-immune-resistance in cancer. Int J Mol Sci. 2019;20(10):E2505.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"327_CR26","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1038\/oncsis.2016.32","volume":"5","author":"CE Henry","year":"2016","unstructured":"Henry CE, Llamosas E, Djordjevic A, Hacker NF, Ford CE. Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis. 2016;5(5):e226.","journal-title":"Oncogenesis"},{"issue":"5","key":"327_CR27","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.tranon.2018.07.010","volume":"11","author":"K Veskim\u00e4e","year":"2018","unstructured":"Veskim\u00e4e K, Scaravilli M, Niininen W, Karvonen H, Jaatinen S, Nykter M, et\u00a0al. Expression analysis of platinum sensitive and resistant epithelial ovarian cancer patient samples reveals new candidates for targeted therapies. Transl Oncol. 2018;11(5):1160\u201370.","journal-title":"Transl Oncol"},{"issue":"11","key":"327_CR28","doi-asserted-by":"publisher","first-page":"e27308","DOI":"10.1371\/journal.pone.0027308","volume":"6","author":"M Bordonaro","year":"2011","unstructured":"Bordonaro M, Tewari S, Cicco CE, Atamna W, Lazarova DL. A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS ONE. 2011;6(11):e27308.","journal-title":"PLoS ONE"},{"issue":"6","key":"327_CR29","doi-asserted-by":"publisher","first-page":"e0234078","DOI":"10.1371\/journal.pone.0234078","volume":"15","author":"SR Sennoune","year":"2020","unstructured":"Sennoune SR, Nelius T, Jarvis C, Pruitt K, Kottapalli KR, Filleur S. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells. PLoS ONE. 2020;15(6):e0234078.","journal-title":"PLoS ONE"},{"issue":"11","key":"327_CR30","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00018-013-1485-z","volume":"71","author":"L Li","year":"2014","unstructured":"Li L, Ying J, Tong X, Zhong L, Su X, Xiang T, et\u00a0al. Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting \u03b2-catenin and AKT signaling but frequently methylated in common carcinomas. Cell Mol Life Sci. 2014;71(11):2179\u201392.","journal-title":"Cell Mol Life Sci"},{"issue":"13","key":"327_CR31","doi-asserted-by":"publisher","first-page":"13115","DOI":"10.18632\/aging.103400","volume":"12","author":"M Guo","year":"2020","unstructured":"Guo M, Ma G, Zhang X, Tang W, Shi J, Wang Q, et\u00a0al. ROR2 knockdown suppresses breast cancer growth through PI3K\/ATK signaling. Aging. 2020;12(13):13115\u201327.","journal-title":"Aging"},{"issue":"2","key":"327_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3727\/096504016X14732772150424","volume":"25","author":"C Yang","year":"2017","unstructured":"Yang C, Ji S, Li Y, Fu L, Jiang T, Meng F. Ror2, a developmentally regulated kinase, is associated with tumor growth, apoptosis, migration, and invasion in renal cell carcinoma. Oncol Res. 2017;25(2):195\u2013205.","journal-title":"Oncol Res"},{"issue":"1","key":"327_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12967-019-02178-x","volume":"17","author":"R Li","year":"2019","unstructured":"Li R, Liu T, Shi J, Luan W, Wei X, Yu J, et\u00a0al. ROR2 induces cell apoptosis via activating IRE1\u03b1\/JNK\/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo. J Transl Med. 2019;17(1):428.","journal-title":"J Transl Med"},{"issue":"6","key":"327_CR34","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.3892\/etm.2016.3883","volume":"12","author":"L Yan","year":"2016","unstructured":"Yan L, Du Q, Yao J, Liu R. ROR2 inhibits the proliferation of gastric carcinoma cells via activation of non-canonical Wnt signaling. Exp Ther Med. 2016;12(6):4128\u201334.","journal-title":"Exp Ther Med"},{"issue":"5","key":"327_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/1523-1747.ep12381544","volume":"102","author":"J L\u00fcbbe","year":"1994","unstructured":"L\u00fcbbe J, Reichel M, Burg G, Kleihues P. Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol. 1994;102(5):819\u201321.","journal-title":"J Invest Dermatol"},{"key":"327_CR36","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.biopha.2017.11.091","volume":"97","author":"C Feng","year":"2018","unstructured":"Feng C, Xian Q, Liu S. Micro RNA-518 inhibits gastric cancer cell growth by inducing apoptosis via targeting MDM2. Biomed Pharmacother. 2018;97:1595\u2013602.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"327_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/0284186X.2018.1541252","volume":"58","author":"T Maeda","year":"2019","unstructured":"Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, et\u00a0al. The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma. Acta Oncol. 2019;58(3):379\u201381.","journal-title":"Acta Oncol"},{"issue":"6","key":"327_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/CMR.0000000000000592","volume":"29","author":"U Swami","year":"2019","unstructured":"Swami U, Monga V, Freesmeier M, Zhang W, Bossler AD, Zakharia Y, et\u00a0al. Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma. Melanoma Res. 2019;29(6):643\u20137.","journal-title":"Melanoma Res"},{"issue":"10","key":"327_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fonc.2020.00070","volume":"14","author":"R Hadash-Bengad","year":"2020","unstructured":"Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G, et\u00a0al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma\u2014a retrospective study. Front Oncol. 2020;14(10):70.","journal-title":"Front Oncol"},{"issue":"3","key":"327_CR40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000504578","volume":"98","author":"GS Karachaliou","year":"2020","unstructured":"Karachaliou GS, Ayvali F, Collichio FA, Lee CB, Ivanova A, Ollila DW, et\u00a0al. Chemotherapy following PD-1 inhibitor blockade in patients with unresectable Stage III\/Stage IV metastatic melanoma: a single academic institution experience. Oncology. 2020;98(3):174\u20138.","journal-title":"Oncology"},{"issue":"7","key":"327_CR41","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41416-021-01486-8","volume":"125","author":"S Bouchereau","year":"2021","unstructured":"Bouchereau S, Chaplain L, Fort M, Beauchet A, Sidib\u00e9 T, Chapalain M, et\u00a0al. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. Br J Cancer. 2021;125(7):948\u201354.","journal-title":"Br J Cancer"},{"issue":"4","key":"327_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","volume":"30","author":"J Vera Aguilera","year":"2020","unstructured":"Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, Kumar AB, et\u00a0al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30(4):364\u201375.","journal-title":"Melanoma Res"},{"issue":"2","key":"327_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","volume":"6","author":"CE Ariyan","year":"2018","unstructured":"Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, et\u00a0al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res. 2018;6(2):189\u2013200.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"327_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/COC.0000000000000644","volume":"43","author":"SN Markovic","year":"2020","unstructured":"Markovic SN, Suman VJ, Javed A, Reid JM, Wall DJ, Erickson LA, et\u00a0al. Sequencing ipilimumab immunotherapy before or after chemotherapy (nab-paclitaxel and bevacizumab) for the treatment of BRAFwt (BRAF Wild-Type) metastatic malignant melanoma: results of a study of academic and community cancer research united (ACCRU) RU261206I. Am J Clin Oncol. 2020;43(2):115\u201321.","journal-title":"Am J Clin Oncol"},{"key":"327_CR45","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.2147\/OTT.S182721","volume":"11","author":"S Kakadia","year":"2018","unstructured":"Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, et\u00a0al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018;11:7095\u2013107.","journal-title":"Onco Targets Ther"},{"issue":"12","key":"327_CR46","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/2159-8290.CD-13-0005","volume":"3","author":"MP O\u2019Connell","year":"2013","unstructured":"O\u2019Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, et\u00a0al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013;3(12):1378\u201393.","journal-title":"Cancer Discov"},{"issue":"31","key":"327_CR47","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1038\/s41388-021-01879-2","volume":"40","author":"J Alonso-Mara\u00f1\u00f3n","year":"2021","unstructured":"Alonso-Mara\u00f1\u00f3n J, Villanueva A, Piulats JM, Mart\u00ednez-Iniesta M, Sol\u00e9 L, Mart\u00edn-Liberal J, et\u00a0al. Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair. Oncogene. 2021;40(31):5042\u20138.","journal-title":"Oncogene"},{"key":"327_CR48","first-page":"549","volume":"16","author":"F Ahmed","year":"2021","unstructured":"Ahmed F, Tseng H-Y, Ahn A, Gunatilake D, Alavi S, Eccles M, et\u00a0al. Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF\/MAPK inhibitor resistant melanoma. J Invest Dermatol. 2021;16:549.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"327_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et\u00a0al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1186\/s11658-022-00357-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000}}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-022-00327-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-022-00327-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-022-00327-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T20:02:50Z","timestamp":1656878570000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-022-00327-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1186\/s11658-022-00327-7","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s11658-022-00357-1","asserted-by":"object"}]},"ISSN":["1425-8153","1689-1392"],"issn-type":[{"value":"1425-8153","type":"print"},{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s11658-022-00357-1","URL":"https:\/\/doi.org\/10.1186\/s11658-022-00357-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}